ARS Pharmaceuticals SPRY
NASDAQ SPRY
$4.12 -0.19 (-4.41%)
At close: Oct 1, 2026 · 4:00 PM EDT

ARS Pharmaceuticals (SPRY) Liabilities and Shareholders Equity (2020 - 2026)

Updated

ARS Pharmaceuticals' Liabilities and Shareholders Equity was $249.5 million in Q2 2026, down 20.4% from $313.47 million a year earlier and down 13.2% from the prior quarter.

Analysis

ARS Pharmaceuticals (SPRY) Liabilities and Shareholders Equity (2020 - 2026) Analysis & Trends

At the end of FY2025, Liabilities and Shareholders Equity at ARS Pharmaceuticals came in at $327.65 million, down 6.7% from FY2024.

  • Liabilities and Shareholders Equity shows a five-year compound annual growth rate of -3.7% (FY2020 to FY2025).
  • In earlier years, Liabilities and Shareholders Equity was $351.15 million in FY2024 (+50.6%), $233.19 million in FY2023 (-17.1%), $281.44 million in FY2022 (+358.0%) and $61.45 million in FY2021 (-84.4%).
  • The Q2 2026 figure marks the lowest quarterly Liabilities and Shareholders Equity since Q3 2024.
  • Compared with a year earlier, Liabilities and Shareholders Equity has declined for three straight quarters, with growth averaging 19.4% over the last eight quarters.
  • The best year-over-year quarter for Liabilities and Shareholders Equity over five years was Q4 2022 (growth of 358.0%); the worst was Q4 2021 (a decline of 84.4%).
  • Per Business Quant data, SPRY's Liabilities and Shareholders Equity in the three quarters before Q2 2026 was $287.57 million (Q1 2026), $327.65 million (Q4 2025) and $372.8 million (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn 201.06 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn 135.12 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn 129.80 Bn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn 122.03 Bn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn 115.83 Bn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn 95.64 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn 49.36 Bn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn 201.13 Bn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn 27.42 Bn
10 ARS Pharmaceuticals 428.58 Mn 284.78 Mn 20.81 Mn 249.50 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 249.50 Mn
Mar 31, 2026 287.57 Mn
Dec 31, 2025 327.65 Mn
Sep 30, 2025 372.80 Mn
Jun 30, 2025 313.47 Mn
Mar 31, 2025 327.32 Mn
Dec 31, 2024 351.15 Mn
Sep 30, 2024 217.60 Mn
Jun 30, 2024 221.97 Mn
Mar 31, 2024 227.58 Mn
Dec 31, 2023 233.19 Mn
Sep 30, 2023 248.56 Mn
Jun 30, 2023 258.75 Mn
Mar 31, 2023 271.19 Mn
Dec 31, 2022 281.44 Mn
Sep 30, 2022 271.06 Mn
Jun 30, 2022 294.00 Mn
Mar 31, 2022 312.47 Mn
Dec 31, 2021 61.45 Mn
Sep 30, 2021 352.56 Mn
API Access

ARS Pharmaceuticals Liabilities and Shareholders Equity API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=liabilities-and-shareholders-equity&ticker=SPRY&period=max&api_key=YOUR_API_KEY